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Abstract
Background: When faced with uncertainties about the effects of medical interventions regulatory agencies,
guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more
randomized trials. The conduct of additional randomized trials is, however, sometimes not the most efficient
way to reduce uncertainty. Instead, approaches such as value of information analysis or other approaches
should be used to prioritize research that will most likely reduce uncertainty and inform decisions.
Discussion: In situations where additional research for specific interventions needs to be prioritized, we propose
the use of quantitative benefit–harm assessments that illustrate how the benefit–harm balance may change as a
consequence of additional research. The example of roflumilast for patients with chronic obstructive pulmonary
disease shows that additional research on patient preferences (e.g., how important are exacerbations relative to
psychiatric harms?) or outcome risks (e.g., what is the incidence of psychiatric outcomes in patients with chronic
obstructive pulmonary disease without treatment?) is sometimes more valuable than additional randomized trials.
Summary: We propose that quantitative benefit–harm assessments have the potential to explore the impact of
additional research and to identify research priorities Our approach may be seen as another type of value of
information analysis and as a useful approach to stimulate specific new research that has the potential to change
current estimates of the benefit–harm balance and decision making.
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Background
Roflumilast, a phosphodiesterase-4 inhibitor, has been ap-
proved, after a long regulatory process in the US and EU,
for the prevention of exacerbations in patients with severe
chronic obstructive pulmonary disease (COPD) and fre-
quent exacerbations [1, 2]. Despite a carefully-conducted
Cochrane systematic review based on high-quality ran-
domized controlled trials (RCTs) [3], regulators, guideline
developers, researchers and clinicians alike find it difficult
to interpret these data [4–6]. Decisions or recommenda-
tions for or against drugs are commonly made under con-
siderable uncertainty because it is unclear how relevant
the beneficial (and statistically significant) effects are for
(various) types of patients, who may or may not be vulner-
able to particular side effects, or because long-term data
and data from patients with comorbidities and co-
medications are lacking [7–9].
Regulatory agencies, guideline developers, researchers
and funding agencies commonly ask for more research
when faced with such uncertainties. Often, such calls are
not explicit with respect to defining what the uncertainty
is about and how specific further research is likely to re-
duce it. Greenhalgh called the statement “more research
is needed” the “most over-used and under-analyzed
statement in the academic vocabulary” [10]. Others
called for a 10-year moratorium on trials (“No More
Cookbook Randomized Controlled Trials”) and a greater
focus on the needs of practitioners, patients, payers, and
policymakers in order to prioritize research [11]. The
main sources of uncertainty, however, may be difficult to
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identify. Assessing how consequential specific additional
research will be in order to augment the existing evi-
dence can be hard, too.
Box 1 shows the research needs identified by the
Cochrane review on roflumilast [3]. Nearly all of these
needs can be addressed by RCTs. While each of the
needs addresses an uncertainty about the evidence base,
no prioritization is suggested.
Research prioritization is challenging because various
stakeholders have their own perspectives and interests
[12]. For example, the researchers themselves may ask
for more research that fits their research agenda [13].
Patients and the general public, if asked, might request
research that informs their decisions for or against med-
ical interventions [14, 15]. Funding agencies have an
interest in groundbreaking research and in wisely spend-
ing scarce resources on research with high relevance for
patients’ quality of life, morbidity and mortality [16, 17].
Additional stakeholders, such as public and private fund-
ing agencies, industry, payers, and politicians, may bring
yet another set of preferences for research priorities.
Approaches to research prioritization
Research prioritization has gained much interest over
the past 20 years. The goal of research prioritization is to
rank-order research questions for specific stakeholders
(e.g., patients or policymakers). In 2004, Fleurence and
Torgerson provided a framework of approaches to re-
search prioritization [18], distinguishing between five
groups of approaches: burden of disease, subjective
methods, impact on clinical variation, payback expec-
tations, and value of information analyses (VOI). Box 2
provides a brief description of these five approaches. Cur-
rently, subjective approaches are probably most com-
monly used, but VOI has gained popularity among larger
funding agencies such as the National Institute for Health
and Clinical Excellence in the UK, the Agency for Health-
care Research and Quality (AHRQ), the Patient-Centered
Outcomes Research Institute, and the National Institutes
of Health [19–22].
The choice of approach to research prioritization
partly depends on whether disease areas and/or risk fac-
tors are rank-ordered, or within disease areas, whether
specific research questions about causal factors, diagnos-
tic procedures, prognostic factors, and treatments are to
be prioritized. For example, funding bodies, such as
AHRQ, which sometimes take a “burden of disease” ap-
proach [23, 24] and specifically ask for research pro-
posals on diseases (e.g., cardiovascular disease, cancer or
respiratory disease) or risk factors (e.g., smoking or
physical inactivity) with high burden for society [17], or
the Bill and Melinda Gates foundation, which typically
prioritizes research on diseases with high burden for de-
veloping countries such as malaria, tuberculosis, or HIV
[25]. From a health systems perspective, it may be attract-
ive to identify areas of clinical care where there is much
practice variation and to prioritize research that has the
potential to limit practice variation around best practices
and get some payback, for example, by determining how
Box 1: Research needs identified by a Cochrane
systematic review [3]
Patient population
 Subgroup analysis in patients with/without chronic
bronchitis and with/without history of exacerbations
 Effect of phosphodiesterase-4 (PDE4) inhibitors in patients
with frequent exacerbations
 Use of PDE4 inhibitors in acute exacerbations
Intervention (no research needs identified)
Comparator
 A direct comparison of PDE4 inhibitors and inhaled
corticosteroid (ICS), when used as add-on therapies to either
tiotropium or long-acting beta-2 agonists, or both
 A direct comparison of either tiotropium or long-acting
beta-2 agonists, or both, as add-on therapies to PDE4 inhibi-
tors (± ICS)
Outcomes
 Longer-duration studies to look at the effect of PDE4
inhibitors on forced expiratory volume in 1 second (FEV1)
decline and mortality
 Effect of PDE4 inhibitors on healthcare utilization, including
hospitalization (incidence and bed days)
 Effect of roflumilast on quality of life
 Better characterization of the weight loss seen with PDE4
inhibitors in COPD
 Better description of the nature of the effect on the
exacerbations that do occur
 Cost-effectiveness of PDE4 inhibitors
 Ascertaining exercise tolerance data for roflumilast
 Determining if there is any benefit on cardiovascular
outcomes with PDE4 inhibitors in COPD
Other
 Using the effects of PDE4 inhibitors to better understand the
pathophysiology of COPD
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much of which type of health care is minimally required
to ensure good patient outcomes [26–28].
When research priorities within disease areas (e.g.,
COPD) need to be set, the selected research questions
are often about the (comparative) effectiveness of spe-
cific interventions (e.g., different drug treatments) across
populations and outcomes, including costs. Subjective
methods, where the patients’ and clinicians’ perspective
can be brought in, are commonly used [13, 15, 29, 30].
Studying the impact on clinical variation, payback expec-
tations, and VOI are also approaches to define research
priorities within disease areas. VOI is arguably the most
versatile approach that can be used for various tasks of
research prioritization [19, 31].
The benefit–harm balance as an additional dimension to
assess the potential impact of additional evidence
When setting research priorities at the level of specific
interventions and comparisons, we propose that it may,
at least occasionally, be useful to focus on the benefit–
harm balance as the key parameter to decide on research
priorities. Estimating the benefit–harm balance is a core
activity of regulatory agencies and clinical guideline de-
velopers who must decide for or against preventive or
therapeutic drug or non-drug treatments. Patients and
clinicians, more or less explicitly, consider the benefit–
harm balance before making decisions. As so often,
where there is uncertainty about the benefit–harm bal-
ance of a certain treatment, we argue that research that
has the potential to reduce uncertainty should be priori-
tized, similar to VOI methods. Priorities should be set
for research that potentially changes the current esti-
mate of the benefit–harm balance or makes it more pre-
cise, and as a consequence of an updated benefit–harm
balance, impacts on (variability of ) decision making. If
additional research is unlikely to change the current esti-
mate of the benefit–harm balance, it is unlikely that it
will have an impact on practice.
To illustrate that, we focus on the quantitative assess-
ment of the benefit–harm balance of roflumilast [32].
Such quantitative assessments may include cost, but
costs are beyond the scope of this article. Several reviews
have discussed quantitative approaches for benefit–harm
assessment [33–35]. Conceptually, it is useful to distin-
guish between quantitative approaches that deal with
single or very few benefit and harm outcomes and those
that deal with multiple benefit and harm outcomes, and
multiple categories thereof (e.g., mild, moderate, and se-
vere COPD exacerbations) [34]. For example, balancing
the reduction in moderate to severe COPD exacerba-
tions versus increase in any gastrointestinal or psychi-
atric harm is often made using a comparison of the
number-needed-to-treat and number-needed-to-harm.
Often, as we and others have argued [34, 35], this
Box 2: Approaches for research prioritization
(organized according to Fleurence and Torgerson [18])
Burden of disease
A common approach to prioritize research is to use measures of
disease burden such as mortality, disability-adjusted life years, cost
of illness, or others. As a result, there is an enormous body of evi-
dence on risk factors and (preventive) treatments for major cardio-
vascular diseases, major infectious diseases (e.g., HIV), major chronic
lung diseases, and major cancers as opposed to scarce literature on
risk factors and treatment effectiveness for rare(r) diseases.
Subjective methods
Subjective methods employ expert knowledge and experiences
to define areas of research that warrant higher priority than
others. Subjective methods have been criticized because they
are usually not transparent. However, more recently, a number
of approaches have been developed that use knowledge and
experience of experts in a more systematic and replicable way
and in combination with systematic reviews.
Impact on clinical variation
This approach assumes that variations in clinical practice result
from uncertainty about the (comparative) effectiveness of
interventions and disagreement among health care providers.
Additional research is prioritized that has the potential to reduce
uncertainty and, thereby, reduce variations in clinical practice. The
Women’s Health Initiative trial is an example of how a randomized
controlled trial (RCT) may change prescription rates (in this case, of
post-menopausal hormone replacement therapy).
Payback expectations
This approach foresees the impact of research on clinical variation
but also takes into consideration the cost of additional research
(e.g., a large-scale RCT). Payback refers to the money that is saved
in the future as a result of the investment in research.
Value of information
Value of information analysis estimates the impact of research on
health outcomes and cost including the costs of conducting the
research. Value of information analyses make the key determinants
of uncertainty about the (comparative) effectiveness of
interventions explicit and uses extensive modelling techniques to
predict how additional research reduces uncertainty, and as a
consequence, how the implementation of a new or an alternative
intervention in practice and (parts of the) population will change
health outcomes. This approach is highly flexible and allows
prioritizing research in diverse contexts.
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oversimplifies the problem and one may want to use
more sophisticated statistical approaches that consider
multiple benefit and harm outcomes as well as a bene-
fit–harm metric. Examples for those approaches include
multi-criteria decision analysis, transparent uniform risk
benefit overview, or the approaches developed by the Na-
tional Cancer Institute (NCI) [36] and the PROTECT con-
sortium (Pharmacoepidemiological Research on Outcomes
of Therapeutics by a European Consortium) [37].
Common to most approaches for quantitative benefit–
harm assessment is that they are based on aggregated
data, consider three key pieces of evidence as reported
previously [38] (Fig. 1), and use statistical models to esti-
mate the benefit–harm balance: treatment effects (typic-
ally available as relative treatment effect estimates from
RCTs or meta-analyses), absolute outcome risks (avail-
able from observational studies or, if not, from control
groups of RCTs), and importance of outcomes (i.e.,
which outcomes are more important than others, avail-
able from preference-eliciting surveys among patients or
based on prognosis associated with the outcomes). Some
approaches (e.g., benefit-less-risk analysis or the ap-
proach described by Boers et al. [39]) consider individual
patient data, which allows for the consideration of the
joint distribution of benefit and harm outcomes [39, 40].
Most quantitative benefit–harm assessments combine
different data sources, each of which provide the best
available estimates for treatment effects, outcome risks,
and importance of outcomes (e.g., through patient pref-
erences), respectively.
We know of no RCT that, on its own, provides enough
data to estimate the benefit–harm balance. Often, a sin-
gle trial, even if a large phase III trial, may provide pre-
cise estimates for the primary and some secondary
outcomes. However, it is very unlikely that a single trial
is powered enough for all outcomes including harms.
This is even more true for baseline risk, where trials are
often of limited value because the eligibility criteria (e.g.,
to make a trial as safe as possible) or selection of pa-
tients into trials may not give estimates of baseline risks
that reflect real world patients. Further, some outcomes
are just too rare so that baseline risks from a single trial
are estimated imprecisely. Finally, trials rarely assess pa-
tient preferences. Although it would be welcome if pref-
erence elicitation surveys were embedded in trials, it
rarely happens. Thus, RCTs may only under very excep-
tional circumstances provide the best available evidence
for all three key pieces that are combined in quantitative
benefit–harm assessments. Of course, the importance of
careful and transparent selection of the most appropriate
data for a quantitative benefit–harm assessment cannot
be emphasized enough [34, 35, 37].
Benefit–harm curves for illustrating the impact of
additional research
We propose that quantitative benefit–harm assessment
is valuable for setting research priorities as illustrated in
Fig. 2a–c. We based these examples on a recent quanti-
tative benefit–harm assessment of roflumilast that used
the NCI approach (Box 3) [32]. One of the main ana-
lyses compared the expected outcomes of 10,000 male
COPD patients below 65 years of age who received
roflumilast over the course of 1 year with 10,000 male
COPD patients below 65 years of age who did not re-
ceive roflumilast. We assumed that these patients had an
intermediate (i.e., 30 %) risk of a moderate to severe ex-
acerbation over the course of a year without roflumilast
(i.e., the baseline risk), which corresponds to the ap-
proved indication for roflumilast.
Randomized trials or meta-
analysis of randomized trials 
Observational studies (cohort studies or registries)
Control groups of randomized trials 
Surveys (preferences)
Observational studies (prognosis)
Various methods
See[33-35] 
Outcome risks
Estimates of effect
Absolute effects
Benefit harm 
analysis
Importance of 
Outcomes
Fig. 1 Key determinants of the benefit–harm balance of interventions. Figure adapted from Yu et al. [38]
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The black (thick-lined) benefit–harm curve in Fig. 2a–c
shows the distribution of 100,000 repetitions of the bene-
fit–harm analysis for this scenario (10,000 male COPD pa-
tients <65 years with a 30 % 1-year risk of moderate to
severe exacerbations). For each repetition, we calculated
the index as the sum of benefit outcome events (i.e., pre-
vented exacerbations) and harm outcome events (psychi-
atric, gastrointestinal, and neurological), based on a
survival model and with weights as described in Box 3.
The 100,000 repetitions take into consideration the statis-
tical uncertainty of treatment effects on benefit and harm
outcomes and of the outcome risks. A negative index
means that the harms exceed the benefits. Almost all of
the repetitions showed a negative index indicating that the
probability that roflumilast is harmful for this scenario
(male COPD patients <65 years with a 30 % 1-year risk of
moderate to severe exacerbations) is very high, or, the
probability of net benefit is close to 0 %.
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of roflumilast.
Impact of smaller and greater weight for exacerbations 
on the benefit–harm balance of roflumilast.
Impact of harm outcome risk on the benefit–harm 
balance of roflumilast.
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c
Fig. 2 Benefit–harm curves for 100,000 estimates of the benefit-harm index (each curve) for roflumilast: IR, Incidence rate; IRR, Incidence rate ratio
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We argue that research that has the potential to shift
(change) or, if the benefit–harm curve overlaps with zero,
can narrow the benefit–harm curves (i.e., make it more
precise) should be prioritized. In addition, research that is
likely to shift a benefit–harm curve in such fashion that
the new curve can support different decisions (e.g., regula-
tory decisions or guideline recommendations) should also
be prioritized. Since such decisions may refer to an entire
population or subpopulations (e.g., COPD patients with
severe disease and at high risk for exacerbations), add-
itional studies may focus on subpopulations or use en-
richment designs to have more statistical power for a
particular subpopulation.
In Fig. 2a, the scenarios with evidence from additional
RCTs are shown. If an additional RCTs comparing roflu-
milast with placebo became available, the most likely
scenario is that it would not change the meta-analytic
estimate of the exacerbation incidence rate ratio import-
antly, but narrow the curve because of a more precise
(meta-analytic) effect estimate (shown by the blue
curve). In another scenario, a very large additional RCT
or a high-quality and large observational study could, if
showing a much larger treatment effect, shift the meta-
analytic treatment effect estimate towards a considerably
larger value and thus shift the benefit–harm curve to-
wards zero, increasing the probability that roflumilast
provides net benefit (shown by the green curve). How-
ever, this scenario is unlikely given the stability (inertia)
of the existing meta-analytic estimate and the substantial
amount of evidence needed to cause such a major shift.
How about a RCT or an observational comparative ef-
fectiveness study where roflumilast is assessed as an
add-on treatment to inhaled drug treatments? There
have been some criticisms that the RCTs on roflumilast
did not explicitly consider co-medications such as long-
acting bronchodilators and inhaled corticosteroids, which
raised concerns about the applicability of the trial results
in real-world populations. In fact, the Food and Drug Ad-
ministration (FDA) asked the manufacturer of roflumilast
for a post-marketing commitment and “Conduct a con-
trolled clinical trial to evaluate the efficacy of roflumilast
as an add-on therapy to a long-acting beta agonist and in-
haled corticosteroid fixed-dose combination therapy in
the population of COPD patients for which roflumilast is
indicated” [2]. To call for such a post-marketing commit-
ment shows, similar to the research needs identified by
the Cochrane review, a focus on research questions that
can be addressed by RCTs.
However, it is unlikely that such a trial would show a
larger treatment effect than existing trials that compared
roflumilast against placebo on top of unclear co-
treatments. Furthermore, the treatment effect can even
be smaller, as is commonly the case in such head-to-
head trials, and shrink the updated meta-analytic esti-
mate. As a consequence the benefit–harm curve would
shift to the left indicating an even more negative bene-
fit–harm balance (red curve). In fact, the RCT, which
the FDA asked the manufacturer of roflumilast to con-
duct for a post-marketing commitment, has been pub-
lished just recently [41]. This RCT found a similar effect
of roflumilast on exacerbations in severe COPD patients
using fixed combinations of inhaled corticosteroids and
long-acting beta-2 agonists as in previous studies (inci-
dence rate ratio of 0.87 [95 % CI, 0.75–1.00]) [41]. The
limited additional information this trial provided sup-
ports our argument against conducting additional RCTs
when the benefit–harm balance is unlikely to change. It
Box 3: Summary of a recent quantitative benefit–harm
analysis on roflumilast for patients with COPD [32]
We used the approach developed by Gail/NCI [36] estimating
the probability that the benefits of an intervention exceed the
harms for COPD patients at different risks for exacerbations. We
considered the effects of roflumilast on exacerbations and harm
outcomes, including gastrointestinal (acute pancreatitis, diarrhea,
nausea, and weight loss), psychiatric (insomnia, anxiety,
depression, and suicide), and neurological (headache and
dizziness) symptoms or disorders based on high-quality RCTs
that were included in the Cochrane review on roflumilast [2]
and in the extensive evaluations of the US FDA [3]. Since harmful
effects were expected from roflumilast, the trials paid particular
attention to harm outcomes and reported remarkably precise
estimates of treatment effects on harm outcomes and baseline
risks, which was valuable for our benefit–harm analysis. Where
trials did not provide valid or precise estimates of baseline risks
we used data from the Centers for Disease Control and Prevention
and from observational studies as reported previously [32]. We
varied the outcome risk and severity of COPD exacerbations
(moderate exacerbations defined as those requiring outpatient
treatment, usually with systemic corticosteroids ± antibiotics,
and severe exacerbations defined as those requiring hospital
admission ± mechanical ventilation) as well as the weight of
different benefit and harm outcomes. Thereby, we could
determine the benefit–harm balance of roflumilast for various
scenarios, clarifying considerably its potential indications.
We used moderate to severe exacerbations as the benefit
outcome and included 10 gastrointestinal, psychiatric, and
neurological events as harm outcomes. In the main analysis, we
assigned a (relative) weight of 1.0 to completed suicide, 0.5 to
incident moderate to severe exacerbations and acute pancreatitis,
0.25 to incident depression, anxiety and insomnia, and 0.05 to
incident diarrhea, nausea, weight loss, headache and dizziness.
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sometimes is not a sensible investment and, from an
ethical point of view, the conduct of such a trial, which
may cost 100 million US$ or more [42], may be ques-
tioned since it is unlikely that the newly estimated bene-
fit–harm balance would lead to a different conclusion
compared to the benefit–harm balance based on existing
evidence.
Figure 2b shows the impact of knowing more about
the importance patients assign to moderate-to-severe ex-
acerbations. There is not much evidence about the im-
portance of exacerbations from a patient’s perspective
relative to other outcomes such as the harms caused by
roflumilast. A preference-eliciting survey among COPD
patients may show that patients are, on average, as con-
cerned about some of the harms (e.g., incidence of de-
pression or anxiety) as they are about exacerbations so
that the relative weight used for the benefit–harm ana-
lysis should be larger. As a consequence, the benefit–
harm curve would shift to the left (Fig. 2b, red curve), or
the survey may show that patients assign more weight to
moderate-to-severe exacerbations relative to the harm
outcomes, which would shift the curve towards zero
(yellow curve). The examples in Fig. 2b suggest that add-
itional evidence about patient preferences may be valu-
able to inform the benefit–harm balance of roflumilast
since the benefit–harm curve is likely to shift.
In the case of roflumilast, there is considerable evi-
dence on harmful effects as the Cochrane review and
FDA documents show. However, it is unclear at what
(absolute) risks COPD patients are to experience the
gastrointestinal, psychiatric, and neurological outcomes
without roflumilast and how much roflumilast increases
those risks. For the black curve in Fig. 2c, we assumed,
based on the placebo groups of the roflumilast trials (for
insomnia and anxiety) and an observational study (for
depression), that the incident rates for depression, anx-
iety and insomnia are around 15 per 1,000 person years.
There is some uncertainty about these incidence rates
since risks in placebo groups often do not reflect risks
observed in real-world populations because of the
eligibility criteria and selection mechanisms in RCTs.
Figure 2c illustrates that additional evidence, which is
more valid and applicable for COPD patients in whom
roflumilast is prescribed in real-world practice, may shift
the benefit–harm curve considerably. If the incident rate
of psychiatric outcomes is in fact higher than current es-
timates, which may well be the case, the benefit–harm
curve would shift to the left (grey curve), meaning that
the benefit–harm balance would become even less favor-
able. In this case, investment in such a cohort study with
COPD patients may not be worthwhile since the conclu-
sion that the benefit–harm balance is unfavorable would
not change. If, however, there is an indication that
current estimates of the incidence rates for depression,
anxiety, and insomnia are overestimated, research in
such an observational study may be justified because the
benefit–harm curve would shift to the right indicating a
more favorable benefit–harm balance for roflumilast
than current estimates suggest (orange curve).
Conclusion
In situations where additional research for specific inter-
ventions in specific populations needs to be prioritized, we
propose that investigators may use benefit–harm assess-
ment as a way to prioritize research. Research prioritization
should not only focus on questions that can be addressed
by new RCTs, but include specific research that has the
potential to shift current estimates of the benefit–harm
balance.
Previous research has identified many methodologies
for quantitative benefit–harm assessment and discussed
the challenges to performing such an assessment [34].
Therefore, these methods, among others to prioritize re-
search, should be assessed for their usefulness in the
process of determining research priorities. The example
of roflumilast shows that the benefit–harm balance is
sometimes more likely to change with additional specific
evidence on patient preferences and outcome risks than
with updated meta-analytic treatment effect estimates
based on additional RCTs. Therefore, we propose that
quantitative benefit–harm assessments have the poten-
tial to explore the impact of additional research and to
identify research priorities.
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